Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06526533 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RECOMMEND Platform Trial

Study acronym: RECOMMEND
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2025 to Mar 23, 2026
    • Site details revised at 3 of 3 sites
    v3
  2. Phase: Early Phase 1 to Phase 3v2 Show 10 more changesShow less
    • Enrollment target: 900 to 600
    • Start date: Sep 2024 to Sep 2025
    • Primary completion date: May 31, 2028 to Jun 2028
    • Study completion date: Nov 30, 2028 to Jun 2029
    • Interventions: Liberal Transfusion (Other), Restrictive Transfusion (Other) to Liberal RBC Transfusion (Other), Restrictive RBC Transfusion (Other)
    • Eligibility criteria expanded, about 139 words
    • Secondary endpoints: 4 to 5
    • Study description shortened, about 49 words
    • Collaborators: 2 to 3
    • Study arms: 2 to 1
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO) The main question the platform trial aims to address is to determine the effect of a range of interventions on survival, organ support and resource utilisation to day 28 for hospitalised patients receiving ECMO. Researchers will compare various interventions within multiple platform trial domains to see if the interventions have effects on survival, organ support and resource utilisation for the patient cohort. Participants will be enrolled in accordance with the platform trial's domain structure to answer the research questions.
Trial Details
NCT Number NCT06526533
Lead Sponsor Australian and New Zealand Intensive Care Research Centre
Collaborators: Monash University, Berry Consultants, Research Path
Conditions
(from sponsor)		 Extracorporeal Membrane Oxygenation Complication, ARDS (Acute Respiratory Distress Syndrome), Intensive Care Medicine, Cardiac Arrest (CA), Critical Illness
Related terms Acute Lung Injury, Critical Illness, Heart Arrest
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov